MAP2K7 and melanoma: However, Yano and colleagues previously reported that the combination treatment of trametinib (a MEK inhibitor; FDA-approved for melanoma, colon cancer and NSCLC) and erlotinib (an EGFR inhibitor; FDA-approved for NSCLC) are effective to eradicate lung cancer cells that carry BRAFG469A (Supplementary Fig. 4)19.